Aurobindo Pharma Limited announced that the United States Food and Drug Administration (US FDA) has classified Unit-I of its wholly owned subsidiary, Eugia Pharma Specialities Limited, as “Official Action Indicated” (OAI). The regulatory action follows an inspection of the formulation manufacturing facility situated at Kolthur Village, Shameerpet Mandal, Ranga Reddy, Telangana.

The inspection was conducted by the US FDA from February 16 to February 27, 2026. During this period, the authority identified four observations at the facility. The company received the formal communication regarding the OAI classification on May 23, 2026.

Details of the Regulatory Action

The classification of OAI signifies that regulatory officials recommend official administrative or regulatory action. This status is assigned when the inspection conditions warrant such measures. Despite the classification, the company has affirmed its commitment to maintaining the highest quality manufacturing standards across its global facilities.

Impact Assessment

In its disclosure to the stock exchanges, Aurobindo Pharma clarified that there is no impact on the company’s financials or operations as a result of this action. The company stated that it would inform the exchanges if any further information regarding the matter arises.

Inspection Summary

Aurobindo Pharma has attracted a range of analyst perspectives, with DAM Capital, Goldman Sachs, and Nuvama all maintaining Buy ratings, while CLSA steps back with a downgrade to Hold — reflecting divergent assessments of the company's near-term performance and longer-term growth trajectory.

Buy Ratings: DAM Capital, Goldman Sachs, and Nuvama

DAM Capital has maintained its Buy rating on Aurobindo Pharma with a target price of ₹1767. The brokerage cites consistent operating performance and strong positioning to benefit from generic industry tailwinds. DAM Capital also highlights the company's investments in biosimilars and injectables, the value-accretive Lannett acquisition, and expected gains from major capital expenditure projects, with easing capex intensity anticipated ahead.

Goldman Sachs has likewise maintained a Buy rating with a target price of ₹1550, noting that the latest quarterly results were broadly in line with expectations. The brokerage points to strong Europe and growth market performance as key drivers, which helped offset weaker US sales stemming from the gRevlimid ramp-down. Goldman Sachs expects high single-digit topline growth and EBITDA margins above 21% in FY27.

Nuvama has also retained a Buy rating with a target price of ₹1680, describing revenue and EBITDA as in line, with strong Europe and growth market performance offsetting weak US growth. The brokerage expects operating leverage benefits from the Pen-G and TheraNym CMO facilities, along with gains from Europe growth and the Lannett deal closure.

BofA Securities Maintains Buy; CLSA Downgrades to Hold

BofA Securities has maintained its Buy rating with a target price of ₹1700, underpinned by stable EBITDA and expectations of margin expansion driven by the ramp-up of the Pen-G plant. The brokerage also highlights management's 21% margin guidance and the Lannett deal as key positives, even as it acknowledges weaker US sales as a headwind.

In contrast, CLSA has downgraded Aurobindo Pharma to Hold, while raising its target price to ₹1490. The brokerage noted that strong Europe growth helped offset US weakness, but margin pressure from higher operating expenditure has tempered its near-term optimism. CLSA acknowledges the company's growth levers — including new product launches, portfolio expansion, and acquisitions — but cautions that meaningful benefits are likely to materialise only from FY28 onwards.

Analyst Ratings at a Glance

The following table summarises the current analyst positions on Aurobindo Pharma:

Diverging Perspectives on Growth Outlook

The range of analyst views reflects differing assessments of how quickly Aurobindo Pharma's growth catalysts will translate into financial performance. DAM Capital, Goldman Sachs, and Nuvama share a constructive outlook, pointing to the Lannett acquisition, biosimilar and injectable investments, and operational leverage from new facilities as near-to-medium term drivers. BofA Securities echoes this optimism, anchoring its Buy on the Pen-G ramp-up and management's margin guidance. CLSA, however, adopts a more cautious stance, preferring to await clearer evidence of sustained US recovery and the realisation of longer-dated growth drivers before turning more positive. Across the board, brokerages recognise the structural positives embedded in the company's portfolio and expansion strategy.